NEW ENGLAND RETINA ASSOCIATES
🇺🇸United States
Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids
Phase 4
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- Device: Dextenza Dexamethasone ImplantDrug: Topical Prednisolone Acetate 1%
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 30
- Registration Number
- NCT04426734
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
Completed
- Conditions
- Epiretinal MembraneAge Related Macular Degeneration
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 16
- Registration Number
- NCT01846351
Ranibizumab as a Rescue Therapy for Diabetic Macular Edema
Phase 2
Withdrawn
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: injection of 0.5 mg of Intravitreal Ranibizumab
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- New England Retina Associates
- Registration Number
- NCT01253694
- Locations
- 🇺🇸
New England Retina Associates, Norwich, Connecticut, United States
Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma
Completed
- Conditions
- Choroidal Melanoma
- Interventions
- Procedure: TTT + ICG-based PDT
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 46
- Registration Number
- NCT01253759
- Locations
- 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Phase 2
Completed
- Conditions
- Choroidal Melanoma
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 10
- Registration Number
- NCT01251978
- Locations
- 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Phase 3
Completed
- Conditions
- Choroidal Melanoma
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 10
- Registration Number
- NCT00680225
- Locations
- 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath